Loading the section…

KURA: financial statements from SEC — TradeAlmanac

KURA

Kura Oncology, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/12/2025	31/12/2024
Revenue	67M	54M
Research and development	251M	170M
Selling, general and administrative	120M	77M
Operating expenses	371M	247M
Operating income	−304M	−193M
Pre-tax income	−278M	−172M
Income tax	297,000	2M
Net income	−279M	−174M
Earnings per share	−3.18	−2.02
Earnings per share, diluted	−3.18	−2.02
Weighted average shares	88M	86M
Weighted average shares, diluted	88M	86M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	39M	149M	95M	82M	51M	224M	49M	45M
Receivables	9M	9M	36M

Cash flow

Metric	31/12/2025	31/12/2024
Operating cash flow	−64M	134M
Depreciation and amortisation	1M	848,000
Share-based compensation	37M	34M
Capital expenditure	7M	472,000
Investing cash flow	−13M	−102M
Financing cash flow	2M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator